$REPL - "On January 21, 2025, Replimune Group . . . issued a new release announcing that the U.S. Food and Drug Administration (#FDA) accepted the Company’s Biologics License Application for RP1 in combination with nivolumab for patients with advanced melanoma." Details at#BeatCancer #Nivolumab #BigPharma #Stocks #Investors #CancerResearch
#REPL #FDA